Q0247 HCPCS code: Injection, sotrovimab, 500 mg
Q0247 is the HCPCS Level II code for injection, sotrovimab, 500 mg. CMS terminated Q0247 on 2024-12-12; do not bill it for later dates of service. In 2022 Medicare paid an average of $203.46 per service for Q0247 across 3,104 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. In 2022, about 354 clinicians billed Medicare for Q0247 for 3,099 beneficiaries; California, Illinois, Tennessee accounted for 35% of services.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 54 |
| BETOS category | O1G — Immunizations/vaccinations |
| Added | 2021-05-26 |
| Last action effective | 2024-12-13 |
| Terminated | 2024-12-12 |
Who bills Q0247 (2022)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 354 |
| Medicare beneficiaries | 3,099 |
| States with claims | 29 |
| Share of services in top 3 states (California, Illinois, Tennessee) | 35% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q0247, 2022–2022
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 3,104 | 3,099 | $203.46 | $203.46 |
States with the most Q0247 services (2022)
| State | Services | Avg. paid |
|---|---|---|
| California | 423 | $181.24 |
| Illinois | 352 | $287.53 |
| Tennessee | 276 | $25.86 |
| Massachusetts | 250 | $0.01 |
| Michigan | 178 | $0.15 |
What changed for Q0247
- 2021-05-26: Q0247 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q0247?
Q0247 is the HCPCS Level II code for injection, sotrovimab, 500 mg. Short descriptor: "Sotrovimab".
How much does Medicare pay for Q0247?
In 2022, the average Medicare payment was $203.46 per service (average allowed $203.46).
Does Medicare cover Q0247?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related Q02 codes
- Q0220 — Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg
- Q0221 — Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
- Q0222 — Injection, bebtelovimab, 175 mg
- Q0224 — Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
- Q0234 — Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
- Q0235 — Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, not otherwise classified, 1 mg
- Q0237 — Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
- Q0238 — Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
- Q0239 — Injection, bamlanivimab-xxxx, 700 mg
- Q0240 — Injection, casirivimab and imdevimab, 600 mg
- Q0243 — Injection, casirivimab and imdevimab, 2400 mg
- Q0244 — Injection, casirivimab and imdevimab, 1200 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q0247
- Watch Q0247 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q0247
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.